Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

Horizon Pharma announces plans for Phase 3 trial of Acctimmune in Friedreich's ataxia

SAN FRANCISCO, CA -- (Marketwired) -- 01/12/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced a business update on its primary care and orphan businesses.

Read More: Horizon Pharma announces plans for Phase 3 trial of Acctimmune in Friedreich's ataxia

SHARE

FacebookTwitterLinkedinShare on Google+
Science A.jpg

News & Press Archives